Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
²¹¹At-OKT10-B10 before Donor Stem Cell Transplant for High-Risk Multiple Myeloma
NCT04579523Phase 1Withdrawn
- Sponsor
- Fred Hutchinson Cancer Center
- Start
- Jun 2027
- Primary completion
- Dec 2028
- Modality
- Monoclonal Antibodies
- Countries
- 1
01
Overview
Phase 1, open-label trial of astatine At 211 OKT10-B10 in multiple myeloma (MM) (2 arms), sponsored by Fred Hutchinson Cancer Center. Primary endpoint: Maximum Tolerated Dose of radiation delivered via ²¹¹At-OKT10-B10 at 100 days. Planned start Jun 2027; status: withdrawn.
02
Drugs
astatine At 211 OKT10-B10
03
Conditions
multiple myeloma (MM)
Beyond the preview
Go deeper on NCT04579523.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT04579523.